NICE says no to Ipsen’s kidney cancer drug
pharmaphorum.com | February 21, 2017
NICE has issued draft guidance which rejects Ipsen’s Cabometyx for NHS use in previously treated advanced renal cell carcinoma (RCC). Cabometyx (cabozantinib), is an important new treatment for the company, and its pivotal trials showed the drug can extend overall survival in previously treated patients, the first such drug to show these benefits.